# NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

> **NCT07502118** · PHASE2,PHASE3 · RECRUITING · sponsor: **Health Institutes of Turkey** · enrollment: 40 (estimated)

## Conditions studied

- Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Relapsed/Refractory Non-Hodgkin Lymphoma
- Diffuse Large B-Cell Lymphoma (DLBCL)
- High-grade B-cell Lymphoma (HGBCL)
- Follicular Lymphoma ( FL)

## Interventions

- **BIOLOGICAL:** Talikabtagene Autoleucel

## Key facts

- **NCT ID:** NCT07502118
- **Lead sponsor:** Health Institutes of Turkey
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-11
- **Primary completion:** 2028-02-01
- **Final completion:** 2030-01-01
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07502118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07502118, "NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07502118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*